Aller au contenu principal
Accès ouvert déclaré 2023 conference-abstract

PA-514 Immunomodulatory activities of atorvastatin on PBMCs from successfully treated TB patients presenting with or without persisting lung inflammation – preliminary findings of StatinTB trial

1Citations signalées — pas une note de qualité
6Institutions déclarées
2Pays d’affiliation déclarés

Résumé fourni par la source

Background Post-TB lung disease (PTLD) is a neglected chronic lung condition that occurs despite successful completion of TB treatment. Statins have broad-range immune-modulatory and anti-inflammatory properties with a potential to reduce PTLD and improve symptoms. In our ongoing StatinTB trial (RIA2017T-2004; NCT04147286), we evaluate safety and efficacy of 40 mg atorvastatin to reduce persistent lung inflammation (PLI) after TB treatment in HIV-/HIV+ adults measured by 18F-FDG-PET/CT. Here we aim to investigate the ex vivo immunomodulatory activities of atorvastatin on peripheral blood mononuclear cells (PBMCs) from treated TB patients following M. tuberculosis infection. Methods At the end of TB treatment, enrolled study participants were subjected to PET/CT scan and. PBMCs were collected at baseline and treated ex vivo with atorvastatin overnight followed by infection with M. tuberculosis (Mtb) HN878 strain. At 24 hours post infection, PBMCs were subjected to flow cytometry to evaluate inflammatory cell surface markers and cell populations. Confocal microscopy was performed to measure phagosome maturation (Rab-7), phagolysosome fusion (Cathepsin-D and LAMP-3) and autophagy (LC3B). CFU and Tunnel assays were conducted to measure intracellular Mtb growth and apoptosis. Results Ex-vivo treatment of PBMC with atorvastatin significantly reduced the intracellular growth of Mtb as measured by CFU assay. Atorvastatin treatment significantly reduced the expression of inflammatory cell surface markers (CD11b and CD16) and decreased classical monocyte (CD14+CD16-) population measured by flow cytometry. The colocalization coefficient of Mtb with the phagosome marker (Rab-7), phagolysosome markers (Cathepsin-D and LAMP-3) and autophagy marker (LC3B) were significantly enhanced by atorvastatin as measured by confocal microscopy. Apoptosis was significantly increased by the treatment of atorvastatin. Conclusion As a host protective mechanism atorvastatin induces phagosome and phagolysosome maturation, autophagy and apoptosis in Mtb-infected PBMCs.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
PA-514 Immunomodulatory activities of atorvastatin on PBMCs from successfully treated TB patients presenting with or without persisting lung inflammation – preliminary findings of StatinTB trial
Date Crossref
01/12/2023
Éditeur
BMJ Publishing Group Ltd
Type
proceedings-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Tuberculosis Research and EpidemiologyCancer, Lipids, and MetabolismBiosimilars and Bioanalytical Methods

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.